ENTIA BIOSCIENCES, INC.
ERGO evidence brief
What we can confirm
- BioSniper Score:
- 2.7 / 10
- Market Cap:
- $20K
- Lead Asset:
- ergod2 (Preclinical)
What it means
What to watch
Prepared research question
What matters most for ERGO—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$20K
Cash Runway
—
Lead Asset
ergod2 (Preclinical)
Next Catalyst
—
Tracking 1 pipeline candidate for ENTIA BIOSCIENCES, INC..
Run ENTIA BIOSCIENCES, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available ENTIA BIOSCIENCES, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Preclinical
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Governance
Frequently asked questions
What is ENTIA BIOSCIENCES, INC.'s lead drug candidate?
ENTIA BIOSCIENCES, INC.'s most advanced tracked candidate is ergod2 (Preclinical) for Chronic kidney disease.
Who is the CEO of ENTIA BIOSCIENCES, INC.?
Mr. Timothy A. Timmins is the chief executive officer of ENTIA BIOSCIENCES, INC. (ERGO).
Where is ENTIA BIOSCIENCES, INC. headquartered?
ENTIA BIOSCIENCES, INC. (ERGO) is headquartered in Sherwood, OR, United States.
What therapeutic areas does ENTIA BIOSCIENCES, INC. focus on?
ENTIA BIOSCIENCES, INC. develops therapies across Oncology, Neurology, Immunology, Hematology, Nephrology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.